Food for thought. A spinoff of LymPro division combined with a partnership at the same time. For shareholders of record after the uplist of course. You may not need a RS in that situation. Rightafter the uplist the Mutual Funds and institutions will pile in, and with revenues the stock price would fair pretty well.

The interest is there. That letter that Barcode found is proof of that. And the statistics have only gotten better. Science will rule the day and we have a front row seat.